Eli Lilly and Company (LLY) to Issue Quarterly Dividend of $1.73 on June 10th

Eli Lilly and Company (NYSE:LLY) announced a quarterly dividend on Monday, May 4th. Shareholders of record on Friday, May 15th will be given a dividend of 1.73 per share on Wednesday, June 10th. This represents a c) annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, May 15th.

Eli Lilly and Company has increased its dividend payment by an average of 0.2%per year over the last three years and has increased its dividend annually for the last 11 consecutive years. Eli Lilly and Company has a payout ratio of 23.3% meaning its dividend is sufficiently covered by earnings. Analysts expect Eli Lilly and Company to earn $44.26 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 15.6%.

Eli Lilly and Company Trading Up 2.4%

Eli Lilly and Company stock opened at $990.11 on Wednesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The firm’s 50-day moving average is $939.93 and its 200-day moving average is $994.31. The company has a market cap of $932.43 billion, a P/E ratio of 35.17, a PEG ratio of 1.05 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the company posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Late-phase trial results showed Foundayo and lower-dose Zepbound helped patients maintain most of their prior weight loss after switching from higher-dose injectable therapies, strengthening Lilly’s obesity franchise. Article: Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss…
• Positive Sentiment: Reuters reported that Lilly launched its Alzheimer’s drug Donanemab, sold as Lormalzi, in India, expanding access to another potential growth product outside the U.S. Article: Eli Lilly launches Alzheimer’s drug Donanemab in India
• Positive Sentiment: Commentary highlighted Lilly as the dominant player in the fast-growing GLP-1 market, which may keep investor sentiment elevated around its obesity and diabetes pipeline. Article: GLP-1 Wars: Winners & Losers
• Positive Sentiment: Barclays raised its price target on LLY to $1,400 from $1,350 and kept an Overweight rating, signaling continued confidence in long-term growth. Article: Barclays Sees Reinforced Long-Term Growth Narrative for Eli Lilly and Company (LLY)

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.